6 research outputs found
Circulating Extracellular Vesicles in Gynecological Tumors: Realities and Challenges
Although liquid biopsy can be considered a reality for the clinical management of some cancers, such as lung or colorectal cancer, it remains a promising field in gynecological tumors. In particular, circulating extracellular vesicles (cEVs) secreted by tumor cells represent a scarcely explored type of liquid biopsy in gynecological tumors. Importantly, these vesicles are responsible for key steps in tumor development and dissemination and are recognized as major players in cell-to-cell communication between the tumor and the microenvironment. However, limited work has been reported about the biologic effects and clinical value of EVs in gynecological tumors. Therefore, here we review the promising but already relatively limited data on the role of circulating EVs in promoting gynecological tumor spread and also their value as non-invasive biomarkers to improve the management of these type of tumors
Impact of extracellular vesicle isolation methods on downstream mirna analysis in semen: A comparative study
Seminal plasma (SP) contains a unique concentration of miRNA, mostly contained in small extracellular vesicles (sEVs) such as exosomes, some of which could be clinically useful for diagnosis and/or prognosis of urogenital diseases such as prostate cancer (PCa). We optimized several exosome-EV isolation technologies for their use in semen, evaluating EV purifying effectiveness and impact on the downstream analysis of miRNAs against results from the standard ultracentrifugation (UC) method to implement the use of SP sEV_miRNAs as noninvasive biomarkers for PCa. Our results evidenced that commercial kits designed to isolate exosomes/EVs from blood or urine are mostly applicable to SP, but showed quantitative and qualitative variability between them. ExoGAG 3500x g and the miRCURY Cell/Urine/CSF 1500x g methods resulted as equivalent alternative procedures to UC for isolating exosomes/sEVs from semen for nanoparticle characteristics and quality of RNA contained in vesicles. Additionally, the expression profile of the altered semen sEV-miRNAs in PCa varies depending on the EV isolation method applied. This is possibly due to different extraction techniques yielding different proportions of sEV subtypes. This is evidence that the exosome-EV isolation method has a significant impact on the analysis of the miRNAs contained within, with important consequences for their use as clinical biomarkers. Therefore, miRNA analysis results for EVs cannot be directly extrapolated between different EV isolation methods until clear markers for delineation between microvesicles and exosomes are established. However, EV extraction methodology affects combined models (semen exosome miRNA signatures plus blood Prostate specific antigen (PSA) concentration for PCa diagnosis) less; specifically our previously described (miR-142-3p + miR-142-5p + miR-223-3p + PSA) model functions as molecular marker from EVs from any of the three isolation methods, potentially improving the efficiency of PSA PCa diagnosis
Enzyme-Loaded Gel Core Nanostructured Lipid Carriers to Improve Treatment of Lysosomal Storage Diseases: Formulation and In Vitro Cellular Studies of Elosulfase Alfa-Loaded Systems
Mucopolysaccharidosis IVA (Morquio A) is a rare inherited metabolic disease caused by
deficiency of the lysosomal enzyme N-acetylgalatosamine-6-sulfate-sulfatase (GALNS). Until now,
treatments employed included hematopoietic stem cell transplantation and enzyme replacement
therapy (ERT); the latter being the most commonly used to treat mucopolysaccharidoses, but with
serious disadvantages due to rapid degradation and clearance. The purpose of this study was
to develop and evaluate the potential of nanostructured lipid carriers (NLCs) by encapsulating
elosulfase alfa and preserving its enzyme activity, leading to enhancement of its biological effect
in chondrocyte cells. A pegylated elosulfase alfa-loaded NLC was characterized in terms of size,
ζ potential, structural lipid composition (DSC and XRD), morphology (TEM microscopy), and
stability in human plasma. The final formulation was freeze-dried by selecting the appropriate
cryoprotective agent. Viability assays confirmed that NLCs were non-cytotoxic to human fibroblasts.
Imaging techniques (confocal and TEM) were used to assess the cellular uptake of NLCs loaded with
elosulfase alfa. This study provides evidence that the encapsulated drug exhibits enzyme activity
inside the cells. Overall, this study provides a new approach regarding NLCs as a promising delivery
system for the encapsulation of elosulfase alfa or other enzymes and the preservation of its activity
and stability to be used in enzymatic replacement therapy (ERT).This research was funded by Xunta de Galicia, grant number GRC2013/015 and GPC2017/015S
Nuevas estrategias en oncologĂa de precisiĂłn: estudio del proceso de anidamiento de cĂ©lulas tumorales circulantes y desarrollo de la tecnologĂa ExoGAG para el aislamiento de vesĂculas extracelulares
La medicina de precisiĂłn basada en la biopsia lĂquida es una herramienta
mĂnimamente invasiva que permite la monitorizaciĂłn en tiempo real de la evoluciĂłn del tumor mediante el anĂĄlisis
de los ĂĄcidos nucleicos libres circulantes, las cĂ©lulas tumorales circulantes (CTC) y las vesĂculas extracelulares
(VEs). En esta tesis, por una parte, se estudiĂł el proceso de adhesiĂłn y anidamiento de las CTC en el contexto del
carcinoma endometrial mediante modelos in vitro e in vivo y se buscaron estrategias para bloquear el proceso de
metĂĄstasis. Por otra parte, se desarrollĂł y optimizĂł la tecnologĂa ExoGAG, una nueva herramienta de aislamiento
de VEs basada en la uniĂłn de un agente de precipitaciĂłn a los glicosaminoglicanos presentes en la superficie de
las VEs. AdemĂĄs, se estudiaron diferentes aplicaciones de la tecnologĂa ExoGAG en la bĂșsqueda de
biomarcadores proteicos y genéticos presentes en las VEs. Finalmente, se establecieron los mecanismos que
permitieron su comercializaciĂłn y se analizaron las estrategias para el traslado de su uso a la prĂĄctica clĂnica